A Phase 1 Study Investigating AGEN1571 as a Single Agent and in Combination With a PD-1 Inhibitor and/or Botensilimab (AGEN1181) in Patients With Advanced Solid Tumors
Latest Information Update: 26 Apr 2024
At a glance
- Drugs AGEN 1571 (Primary) ; Balstilimab (Primary) ; Botensilimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Agenus
- 22 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 05 Jan 2023 Planned End Date changed from 1 Jun 2028 to 20 Jan 2027.
- 05 Jan 2023 Planned primary completion date changed from 1 Jun 2028 to 20 Jan 2027.